Please use this identifier to cite or link to this item:
Title: Cost-effectiveness analysis of parenteral antimicrobials for acute melioidosis in Thailand.
Authors: Hantrakun, Viriya
Chierakul, Wirongrong
Chetchotisakd, Ploenchan
Anunnatsiri, Siriluck
Currie BJ
Peacock, Sharon J
Day, Nicholas P J
Cheah, Phaik Yeong
Cheah, Phaik
Limmathurotsakul, Direk
Lubell, Yoel
Citation: Transactions of the Royal Society of Tropical Medicine and Hygiene 2015-06; 109(6): 416-8
Abstract: Melioidosis is a common community-acquired infectious disease in northeast Thailand associated with overall mortality of approximately 40% in hospitalized patients, and over 70% in severe cases. Ceftazidime is recommended for parenteral treatment in patients with suspected melioidosis. Meropenem is increasingly used but evidence to support this is lacking. A decision tree was used to estimate the cost-effectiveness of treating non-severe and severe suspected acute melioidosis cases with either ceftazidime or meropenem. Empirical treatment with meropenem is likely to be cost-effective providing meropenem reduces mortality in severe cases by at least 9% and the proportion with subsequent culture-confirmed melioidosis is over 20%. In this context, treatment of severe cases with meropenem is likely to be cost-effective, while the evidence to support the use of meropenem in non-severe suspected melioidosis is not yet available.
Click to open PubMed article:
Journal title: Transactions of the Royal Society of Tropical Medicine and Hygiene
Publication Date: 2015-06
Type: Journal Article
Research Support, Non-U.S. Gov't
DOI: 10.1093/trstmh/trv002
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.

Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing